Avelumab
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Avelumab
- Pharmacist Assessment Report
- Avelumab: PD-L1 immune checkpoint inhibitor → human herpesvirus 8-related tumor
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Australia Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Avelumab: PD-L1 immune checkpoint inhibitor → human herpesvirus 8-related tumor
One-Sentence Summary
Avelumab is a monoclonal antibody marketed in Australia as Bavencio. The TxGNN model predicts it may be effective for human herpesvirus 8-related tumor, but the data compiled for this report contain 0 clinical trials and 0 publications for this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | human herpesvirus 8-related tumor |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. The following rationale is therefore general background knowledge and has not been verified against the supplied data.
Avelumab is known to be an antibody directed against PD-L1. HHV-8-related tumors, such as Kaposi sarcoma, can express PD-L1. Blocking PD-L1 could in theory restore antiviral and antitumour T-cell activity. The link is plausible but unverified, and no trial or publication in the compiled data tests it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 11671G | Bavencio | Solution concentrate for I.V. infusion 200 mg in 10 mL | Not recorded in the local data |
Safety Considerations
- Drug Interactions (3 interactions, all rated Major):
- Lenalidomide
- Pomalidomide
- Thalidomide
Warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a model score (0.9997). No clinical trials or publications address this disease, so the evidence level is L5. Mechanism of action data are also missing.
To proceed, the following is needed:
- A targeted literature and trial search on avelumab in HHV-8-related tumors (for example Kaposi sarcoma)
- Mechanism of action data and evidence of PD-L1 expression in these tumors
- Product Information warnings and contraindications from the TGA-approved PI
- Review of the major interactions with lenalidomide, pomalidomide and thalidomide, which are relevant to some HHV-8-related disease settings
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.